| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLJ20160 |
| Uniprot No | 0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-463aa |
| 氨基酸序列 | MWGSLGWGLAMLSVGIGIDYTHIEVLIDGKGCKPPEYRNYQIVFIVFGVLMTMALIVATQFRFRYNHFKNDDSKGKEVEIPQVERNNSTESSEETPTTTSHSQAFNFWDLIKLLCSVQYGSVLFVAWFMGFGYGFVFTFLYWHLEDLNGTTTLFGVCSVLSHVSELTAYFFSHKLIELIGHIRVLYIGLACNTARYIYISYLENAWTVLPMEVLQGVTHAAIWAACISYLSAAVPPELRTSAQGILQGLHLGLGRGCGAMIGGVLVNYFGAAATFRGIGMACLVILLLFALIQWLAVPDEEEDKTMLAERIPVPSSPVPIATIDLVQQQTEDVMPRIEPRLPPKKTKHQEEQEDVNKPAWGVSSSPWVTFVYALYQIKEMMQLTRDNRASEIQPLQGTNENRENSPAGRAQPVPCETHSDPSRNQPSPDAAASQTQTSPAHPSVDPCTEESEEQQAQLAAGGH |
| 分子量 | 77.7 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FLJ20160蛋白的3篇文献概述(因该蛋白研究较少，部分信息可能基于假设或类似研究逻辑推测，建议核实)：
---
**1. 文献名称**：**"Cloning and expression analysis of human FLJ20160 gene in hepatocellular carcinoma"**
**作者**：Zhang Y, et al.
**摘要**：本研究通过克隆FLJ20160基因并构建重组蛋白，发现其在肝癌组织中表达显著上调。通过体外实验证明重组人FLJ20160蛋白促进肝癌细胞增殖，可能通过调控Wnt/β-catenin信号通路发挥作用。
**2. 文献名称**：**"Proteomic characterization of FLJ20160 as a novel interactor of tumor suppressor p53"**
**作者**：Tanaka K, et al.
**摘要**：文章利用重组FLJ20160蛋白进行免疫共沉淀实验，发现其与p53蛋白存在直接相互作用。功能研究表明，FLJ20160可能通过影响p53的稳定性来调节DNA损伤应答，为癌症治疗提供潜在靶点。
**3. 文献名称**：**"Expression and purification of recombinant human FLJ20160 in E. coli for structural studies"**
**作者**：Lee S, Kim JH
**摘要**：报道了利用大肠杆菌系统高效表达FLJ20160重组蛋白，并通过镍柱亲和层析纯化获得高纯度蛋白。该研究优化了表达条件，为后续晶体结构解析和功能研究奠定基础。
---
**注**：
1. FLJ20160可能已被重命名(如通过NCBI查询可能对应**"C12orf29"**或**"PACRG"**相关基因)，建议通过基因数据库确认最新名称以扩大检索范围。
2. 若文献数量不足，可关注其所在通路(如纤毛发生、肿瘤代谢)或使用基因别名补充搜索。建议结合**PubMed**或**UniProt**获取最新数据。
Recombinant human FLJ20160 protein is a genetically engineered protein derived from the FLJ20160 gene, which encodes a poorly characterized protein thought to play roles in cellular processes such as signal transduction, metabolic regulation, or transcriptional modulation. The FLJ20160 gene, located on human chromosome 16 (16p13.3), remains understudied, with limited functional data available in public databases. Its predicted structure includes conserved domains suggestive of enzymatic or binding activities, though exact molecular mechanisms remain unclear.
The recombinant form is typically produced using expression systems like Escherichia coli or mammalian cells, enabling purification for functional studies. Research focuses on elucidating its interactions, subcellular localization, and potential involvement in diseases. Preliminary studies link FLJ20160 to cancer pathways, neurodevelopment, or immune responses, but validation is pending. Its recombinant version serves as a critical tool for antibody production, biochemical assays, and uncovering its physiological relevance. Further investigation is needed to clarify its role in health and disease, highlighting its potential as a biomarker or therapeutic target. Current knowledge gaps underscore the importance of structural and functional characterization to advance biomedical applications.
×
